Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dupilumab

dupilumab

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dupilumab

50 trials tracked of dupilumab: 32 in phase 3 or 4 and 25 with published results. The most-cited published study has 2038 citations.

50Trials tracked
32Phase 3 & 4
0Recruiting
25With published results
Phase distribution
Phase 4 9 Phase 3 23 Phase 2 18
  1. Phase 3 Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Completed · 2,038 cited
  2. Phase 3 Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Completed · 2,034 cited
  3. Phase 3 Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest) Completed · 1,916 cited
  4. Phase 3 Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma Completed · 1,152 cited
  5. Phase 3 A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis Completed · 479 cited
  6. Phase 3 Open-label Study of Dupilumab in Patients With Atopic Dermatitis Completed · 226 cited
Show 44 more trials
  1. Phase 3 A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) Completed · 200 cited
  2. Phase 3 Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Completed · 117 cited
  3. Phase 3 Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) Completed · 104 cited
  4. Phase 4 The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma Completed · 66 cited
  5. Phase 3 A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable Completed · 54 cited
  6. Phase 3 Evaluation of Dupilumab in Children With Uncontrolled Asthma Completed · 49 cited
  7. Phase 3 Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Completed · 37 cited
  8. Phase 3 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Completed · 32 cited
  9. Phase 4 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Completed · 27 cited
  10. Phase 3 Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) Completed · 26 cited
  11. Phase 3 Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis Completed · 26 cited
  12. Phase 3 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Completed · 26 cited
  13. Phase 3 Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) Completed · 10 cited
  14. Phase 3 Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Completed · 3 cited
  15. Phase 4 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis Completed · 1 cited
  16. Phase 3 Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis Completed · 1 cited
  17. Phase 3 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) Completed · 1 cited
  18. Phase 4 The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Completed
  19. Phase 3 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Completed
  20. Phase 4 SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" Completed
  21. Phase 4 A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma Completed
  22. Phase 4 Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma Completed
  23. Phase 4 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Completed
  24. Phase 4 Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Completed
  25. Phase 3 Dupilumab in Chinese Adult Participants With CRSwNP Completed
  26. Phase 3 A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) Completed
  27. Phase 2 Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants Completed
  28. Phase 2 Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Completed
  29. Phase 2 A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) Completed
  30. Phase 2 Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy Completed
  31. Phase 2 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Completed
  32. Phase 2 An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma Completed
  33. Phase 2 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) Completed
  34. Phase 2 Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Completed
  35. Phase 2 Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Completed
  36. Phase 2 An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis Completed
  37. Phase 2 Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients Completed
  38. Phase 2 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed
  39. Phase 2 Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) Completed
  40. Phase 2 Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis Completed
  41. Phase 2 Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD) Completed
  42. Phase 2 Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) Completed
  43. Phase 2 Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy Completed
  44. Phase 2 Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis Completed

Showing the 50 most-cited and recently-updated of 50 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review reframes COPD therapy toward integrated death program modulation by inflammatory endotype
Allergy & Immunology Sys. Review
Review reframes COPD therapy toward integrated death program modulation by inflammatory endotype New research links cell death types to COPD inflammatory patterns
This review synthesizes mechanistic associations between cell death pathways and COPD inflammatory endotypes. The authors describe preferent…
This review suggests specific cell death pathways may help explain how different COPD types respond to treatments like dupilumab.
Frontiers May 13, 2026
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies
Allergy & Immunology Meta-analysis
Switching Biologics in Severe Asthma Patients Shows Improved Clinical Outcomes and Reduced Exacerbations Across Multiple Therapies Switching Asthma Drugs Could Change Your Life
A systematic review and meta-analysis of 2,292 patients found that switching biologics significantly reduced exacerbations and improved asth…
If your severe asthma medication stops working, switching to a different biologic drug could cut your attacks in half and help you breathe e…
May 5, 2026
Meta-analysis shows biologic therapies reduce annual exacerbations in COPD patients with high eosinophils while maintaining safety profiles
Pulmonology & Critical Care Meta-analysis
Meta-analysis shows biologic therapies reduce annual exacerbations in COPD patients with high eosinophils while maintaining safety profiles New drugs cut COPD flare-ups for patients with high eosinophils
This living evidence synthesis evaluates dupilumab and mepolizumab in 7,359 COPD patients. Results indicate reduced annual exacerbation rate…
New biologic drugs lower the yearly number of COPD flare-ups for patients with high eosinophil counts while keeping side effects low
May 3, 2026
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
Neurology Meta-analysis
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy Dupilumab and Pimecrolimus Lead New Rankings for Children's Eczema Relief
This network meta-analysis evaluated dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D for pediatric …
A new analysis ranks the top treatments for children's eczema, with dupilumab and pimecrolimus leading for symptom relief.
Frontiers May 2, 2026
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery
Allergy & Immunology FDA Approval
FDA Approves Dupixent (dupilumab) for Allergic Fungal Rhinosinusitis in Patients with History of Sino-Nasal Surgery FDA approves Dupixent for treating allergic fungal sinus infections in patients who have had sinus surgery
Dupixent (dupilumab) has been approved for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosi…
FDA approves Dupixent for allergic fungal sinus infections in adults and children aged 6 and older who have had sinus surgery.
FDA Apr 21, 2026
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Ophthalmology
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
medRxiv Apr 14, 2026